{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:07:00Z","timestamp":1793650020418,"version":"4.5.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health-Ricerca Corrente"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inotropic therapy is a cornerstone of medical treatment for patients with low-output heart failure (HF). We aimed to investigate the quantitative effect of specific inotropic drugs on invasive haemodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This meta-analysis assessed the haemodynamic effects of dobutamine, levosimendan, and milrinone in patients with low-output HF. Only studies using invasive haemodynamic assessment were included. The primary outcome was the quantitative change in variables such as cardiac index, pulmonary artery wedge pressure, mean pulmonary artery pressure, mean arterial pressure (MAP), pulmonary and systemic vascular resistance (before and after administration of each drug. Quality was assessed using the National Institutes of Health Quality Assessment Tool (NIH-QAT). A sensitivity analysis compared the effect on acute versus chronic HF populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six studies (n = 1888 patients) were included in the analyses. Based on the NIH-QAT checklist, 11 studies were at low risk of bias, 14 at moderate risk, and 1 at high risk. Meta-analysis showed that all the study drugs improved the haemodynamic variables assessed, without significant differences amongst them, except for MAP (P = .0486). Dobutamine and levosimendan caused a non-significant increase in MAP, while milrinone showed a trend towards a reduction in MAP [\u22123.46 (\u22127.27 to +0.35)]. The heterogeneity across studies was high. In the sensitivity analysis, dobutamine improved CI more than levosimendan in patients with chronic HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of inotropes improves haemodynamic status in patients with low-output HF, with no consistent superiority of one agent over the others. These findings support the current clinical practice of agent selection based on individual patient characteristics. Head-to-head trials in well-phenotyped HF populations are warranted to guide personalized inotrope use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag120","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:48:23Z","timestamp":1776858503000},"source":"Crossref","is-referenced-by-count":1,"title":["The quantitative haemodynamic effect of levosimendan, dobutamine, and milrinone in heart failure patients: a meta-analysis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9643-2697","authenticated-orcid":false,"given":"Vincenzo","family":"Nuzzi","sequence":"first","affiliation":[{"name":"Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Via Tricomi 5, Palermo 90127 ,","place":["Italy"]},{"name":"Cardiothoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht (CARIM) , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Madaudo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manca","sequence":"additional","affiliation":[{"name":"Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Via Tricomi 5, Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-6297","authenticated-orcid":false,"given":"Antonio","family":"Cannata","sequence":"additional","affiliation":[{"name":"School of Cardiovascular Medicine and Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7141-2561","authenticated-orcid":false,"given":"Giuseppe","family":"Raffa","sequence":"additional","affiliation":[{"name":"IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Palermo ,","place":["Italy"]},{"name":"Department of Precision Medicine in Medical Surgical and Critical Area (Me.Pre.C.C.), University of Palermo , Palermo 90134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mul\u00e8","sequence":"additional","affiliation":[{"name":"Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Via Tricomi 5, Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-7833","authenticated-orcid":false,"given":"Stefano","family":"Cannata","sequence":"additional","affiliation":[{"name":"Unit of Interventional Cardiology, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eluisa","family":"La Franca","sequence":"additional","affiliation":[{"name":"Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Via Tricomi 5, Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogera","family":"Pisano","sequence":"additional","affiliation":[{"name":"IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Palermo ,","place":["Italy"]},{"name":"Department of Precision Medicine in Medical Surgical and Critical Area (Me.Pre.C.C.), University of Palermo , Palermo 90134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Clinical Cardiology and Heart Failure Unit, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Specialized Therapies) , Via Tricomi 5, Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-2045","authenticated-orcid":false,"given":"Roberto","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht (CARIM) , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026051511115969800_xvag120-B1","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCRESAHA.121.318186","article-title":"Pathophysiology and therapeutic approaches to acute decompensated heart failure","volume":"128","author":"Njoroge","year":"2021","journal-title":"Circ Res"},{"key":"2026051511115969800_xvag120-B2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status\u2014impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"2026051511115969800_xvag120-B4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/ehjacc\/zuae108","article-title":"Cardiogenic shock in general intensive care unit: a nationwide prospective analysis of epidemiology and outcome","volume":"13","author":"Tavazzi","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026051511115969800_xvag120-B5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029787","article-title":"State of shock: contemporary vasopressor and inotrope use in cardiogenic shock","volume":"12","author":"Bloom","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026051511115969800_xvag120-B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026051511115969800_xvag120-B7","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/ehjacc\/zuac127","article-title":"Use of vasodilators in patients with acute heart failure: contra","volume":"11","author":"Mueller","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026051511115969800_xvag120-B8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ehjacc\/zuac128","article-title":"PRO: vasodilators remain an indispensable treatment for acute heart failure","volume":"11","author":"Vanhentenrijk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026051511115969800_xvag120-B9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4103\/2045-8932.113180","article-title":"Comparison of drugs for pulmonary hypertension reversibility testing: a meta-analysis","volume":"3","author":"Guglin","year":"2013","journal-title":"Pulm Circ"},{"key":"2026051511115969800_xvag120-B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012030","article-title":"Gaps and knowledge in the contemporary management of acute right ventricular failure","volume":"18","author":"Manca","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026051511115969800_xvag120-B11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","article-title":"Inotropes","volume":"63","author":"Francis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026051511115969800_xvag120-B12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40256-017-0225-4","article-title":"Effect of milrinone infusion on pulmonary vasculature and stroke work indices: a single-center retrospective analysis in 69 patients awaiting cardiac transplantation","volume":"17","author":"Abramov","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026051511115969800_xvag120-B13","doi-asserted-by":"publisher","first-page":"14A","DOI":"10.1067\/mhj.2001.111404","article-title":"Pharmacodynamic effects of milrinone with and without a bolus loading infusion","volume":"141","author":"Baruch","year":"2001","journal-title":"Am Heart J"},{"key":"2026051511115969800_xvag120-B14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjhf\/hfq032","article-title":"Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers","volume":"12","author":"Bergh","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0003319713485808","article-title":"Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit","volume":"65","author":"Charisopoulou","year":"2014","journal-title":"Angiology"},{"key":"2026051511115969800_xvag120-B16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"2026051511115969800_xvag120-B17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ejheart.2006.01.007","article-title":"Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01331","article-title":"Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: clinical trial FIM-BGC-2014-01","volume":"11","author":"Guerrero-Orriach","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026051511115969800_xvag120-B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/clc.4960190106","article-title":"Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction","volume":"19","author":"Karlsberg","year":"1996","journal-title":"Clin Cardiol"},{"key":"2026051511115969800_xvag120-B20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/00005344-199810000-00016","article-title":"Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure","volume":"32","author":"Kieback","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026051511115969800_xvag120-B21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1074248418797357","article-title":"Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock","volume":"24","author":"Lewis","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026051511115969800_xvag120-B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1054\/jcaf.2001.24136","article-title":"A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure","volume":"7","author":"Loh","year":"2001","journal-title":"J Card Fail"},{"key":"2026051511115969800_xvag120-B24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051511115969800_xvag120-B25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","article-title":"Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure","volume":"40","author":"Metra","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026051511115969800_xvag120-B26","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ejheart.2005.05.001","article-title":"Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure","volume":"7","author":"Moertl","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B27","first-page":"365","article-title":"Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes","volume":"64","author":"Korelitz","year":"1975","journal-title":"Am J Gastroenterol"},{"key":"2026051511115969800_xvag120-B28","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026051511115969800_xvag120-B29","first-page":"III175","article-title":"Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness","volume":"73","author":"Colucci","year":"1986","journal-title":"Circulation"},{"key":"2026051511115969800_xvag120-B30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/ehf2.14379","article-title":"Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure","volume":"10","author":"Rodenas-Alesina","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026051511115969800_xvag120-B31","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1097\/01.CCM.0000287524.17358.48","article-title":"Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock","volume":"35","author":"Russ","year":"2007","journal-title":"Crit Care Med"},{"key":"2026051511115969800_xvag120-B32","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"2026051511115969800_xvag120-B33","first-page":"5624","article-title":"Levosimendan improves cardiac function, hemodynamics, and body inflammation in patients with acute myocardial infarction and heart failure","volume":"15","author":"Sun","year":"2023","journal-title":"Am J Transl Res"},{"key":"2026051511115969800_xvag120-B34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1510\/icvts.2005.122390","article-title":"Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery","volume":"5","author":"Tokuda","year":"2006","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026051511115969800_xvag120-B35","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.jacc.2003.07.004","article-title":"Peripheral sympathetic control during dobutamine infusion","volume":"42","author":"Velez-Roa","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026051511115969800_xvag120-B36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1536\/jhj.40.321","article-title":"Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure","volume":"40","author":"Wimmer","year":"1999","journal-title":"Jpn Heart J"},{"key":"2026051511115969800_xvag120-B37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1067\/mhj.2001.119610","article-title":"Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact","volume":"142","author":"Yamani","year":"2001","journal-title":"Am Heart J"},{"key":"2026051511115969800_xvag120-B38","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.healun.2018.03.011","article-title":"Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock","volume":"37","author":"Fried","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026051511115969800_xvag120-B39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ehf2.15083","article-title":"Haemodynamic effects of intra-aortic balloon pumps stratified by baseline pulmonary artery pulsatility index","volume":"12","author":"Kalapurakal","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026051511115969800_xvag120-B40","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026051511115969800_xvag120-B41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/FJC.0000000000000113","article-title":"Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus","volume":"64","author":"Nagy","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026051511115969800_xvag120-B42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ejhf.2814","article-title":"Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Gustafsson","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ehjacc\/zuac087","article-title":"Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section","volume":"11","author":"Tavazzi","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026051511115969800_xvag120-B44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13613-021-00806-8","article-title":"Current use of inotropes in circulatory shock","volume":"11","author":"Scheeren","year":"2021","journal-title":"Ann Intensive Care"},{"key":"2026051511115969800_xvag120-B45","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026051511115969800_xvag120-B46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response tomilrinone in decompensated heart failure","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026051511115969800_xvag120-B47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jointm.2022.10.003","article-title":"Hemodynamic monitoring in cardiogenic shock","volume":"3","author":"Hamzaoui","year":"2023","journal-title":"J Intensive Med"},{"key":"2026051511115969800_xvag120-B48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13054-025-05356-0","article-title":"Association between mean hemodynamic variables during the first 24 h and outcomes in cardiogenic shock: identification of clinically relevant thresholds","volume":"29","author":"Levy","year":"2025","journal-title":"Crit Care"},{"key":"2026051511115969800_xvag120-B49","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"2026051511115969800_xvag120-B50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2165\/00003088-200746070-00001","article-title":"Clinical pharmacology of levosimendan","volume":"46","author":"Antila","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2026051511115969800_xvag120-B51","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1152\/physrev.00045.2006","article-title":"Regulation of coronary blood flow during exercise","volume":"88","author":"Duncker","year":"2008","journal-title":"Physiol Rev"},{"key":"2026051511115969800_xvag120-B52","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cjca.2022.09.013","article-title":"Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support: results of the DOREMI randomized trial","volume":"39","author":"Jung","year":"2023","journal-title":"Can J Cardiol"},{"key":"2026051511115969800_xvag120-B53","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag120\/68154309\/xvag120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag120\/68154309\/xvag120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag120\/68154309\/xvag120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:12:07Z","timestamp":1778857927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag120\/8661919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag120","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,24]]},"article-number":"xvag120"}}